中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (2): 120-122.doi: 10.12144/zgmfskin202502120

• 临床研究 • 上一篇    下一篇

度普利尤单抗治疗苔藓样皮肤淀粉样变一例

赖美妍1,2,龙博泉1,2,叶智铭1,2,龙绮1,2,杨岚1,2,游馥榕1,2,郭红卫1   

  1. 1 广东医科大学附属第二医院皮肤科，广东湛江，524003; 2 广东医科大学第一临床医学院，广东湛江，524003
  • 出版日期:2025-02-15 发布日期:2025-01-22

Primary cutaneous amyloidosis successfully treated with dupilumab: a case report

LAI Meiyan1,2, LONG Boquan1,2,YE Zhiming1,2, LONG Qi1,2, YANG Lan1,2, YOU Furong1,2, GUO Hongwei1   

  1. 1 Department of Dermatology, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang 524003, China; 2 First School of Clinical Medicine, Guangdong Medical University, Zhanjiang 524003, China
  • Online:2025-02-15 Published:2025-01-22

PDF (PC)

68

摘要： 原发性苔藓样皮肤淀粉样变治疗难度大且复发率高，尚无标准化治疗方案。本文报道一例度普利尤单抗成功治疗原发性苔藓样皮肤淀粉样变。患者项背部、四肢丘疹伴瘙痒2年，经组织病理学确诊。常规治疗效果不佳，给予度普利尤单抗治疗，治疗当日患者瘙痒即减轻，12周后皮疹消退。停药后2个月，未见新发皮疹及不良反应。

关键词: 度普利尤单抗, 原发性皮肤淀粉样变性, 苔藓样淀粉样变

Abstract: Primary cutaneous amyloidosis (PCA) is a refractory disease with high recurrence rate and no standardized treatment. This article reports a case of successful treatment of PCA with dupilumab. The patient presented with papules with itching on the neck and back, and limbs for 2 years, which was confirmed by pathology. Conventional treatments were ineffective, and dupilumab therapy was administered. On the day of treatment, the patient's itching was alleviated, and after 12 weeks, the skin rashes subsided. Two months after drug withdrawal, no new skin rashes or adverse reactions were observed.

Key words: dupilumab, primary cutaneous amyloidosis, lichen amyloidosis